Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

Tasimelteon

EU orphan designation number: EU/3/10/841   
Active ingredient: Tasimelteon
Indication: Treatment of non-24-hour sleep-wake disorders in blind people with no light perception
Sponsor: Vanda Pharmaceuticals Limited
C/O Regus Management (UK) Limited, 81 Oxford Street, London W1D 2EU, United Kingdom

   Public summary of scientific opinion    

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
01/03/2011 Centralised Orphan - Designation EMA/OD/102/10 (2011)1307 of 23/02/2011